Pasithea Therapeutics Corp. (KTTAW) Capital Expenditures (2021 - 2023)

Pasithea Therapeutics has disclosed Capital Expenditures across 3 years of filings, most recently posting -$36.0 for Q4 2023.

• In Q4 2023, Capital Expenditures fell 100.04% year-over-year to -$36.0; the TTM figure through Dec 2023 stood at $34301.0 (down 67.97% YoY), while the FY2023 annual figure was $34301.0, down 67.97% from the prior year.
• Capital Expenditures came in at -$36.0 for Q4 2023 at Pasithea Therapeutics, up from -$22659.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $92725.0 in Q4 2022 to a low of -$22659.0 in Q3 2023.
• Average Capital Expenditures over 3 years is $17148.3, with a median of $5486.0 recorded in 2022.
• The largest YoY upside for Capital Expenditures was 2662.07% in 2023 against a maximum downside of 513.03% in 2023.
• Over 3 years, Capital Expenditures stood at $12933.0 in 2021, then surged by 616.96% to $92725.0 in 2022, then sank by 100.04% to -$36.0 in 2023.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$36.0 in Q4 2023, -$22659.0 in Q3 2023, and $3108.0 in Q2 2023.